CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases
Por:
González-Guerrero, L, Castellet, H, Martinez, Clara, González, N, Guijarro, F, Lloveras, N, Pratcorona, M, Gich, I, Berenguer-Molins, P, Perera-Bel, J, Zamora, L, Mascaró, M, Sampol, A, Garcia-Guiñón, A, Vives, S, Tormo, M, Arnan, M, Villamor, N, Nomdedéu, JF
Publicada:
30 abr 2025
Resumen:
CD200 is a glycoprotein that binds with its receptor CD200R, providing immunosuppressive signals to T and NK cells. CD200 is expressed by normal stem cells and progenitors committed to B-lymphopoiesis and myeloid development. CD200 biological relevance in acute leukemias is only partially understood.The study included a consecutive series of four hundred thirty-one patients with acute myeloid leukemia (AML). Immunophenotype was established by multiparametric flow cytometry, and the genetic diagnosis was performed by PCR-based methods and a targeted resequencing method covering 42 genes.66% of AML patients expressed CD200 being significantly associated with CD34 reactivity. The frequency of CD200 positivity was higher in cases with core-binding factor genetic lesions such as RUNX1-RUNX1T1 (81.3%) fusions and CBFB-MHY11 (63.2%) rearrangements and also with biallelic CEBPA mutations (100%). The molecular AML group with the lowest CD200 reactivity (19.1%) corresponded to AML with NPM1 mutations. RNA seq showed no uniform pattern of infiltrating cells in CEBPA mutated AML. Deconvolution analysis may be used to assess the immunoregulatory mechanisms of AML.CD200 expression could help identify the more immature compartment and, combined with other markers, single out CEPA-mutated AML.
Filiaciones:
González-Guerrero, L:
Univ Autonoma Barcelona, Inst Josep Carreras, Hosp Santa Creu & St Pau, IIB St Pau,Lab Hematol,Hematol Dept, St Quinti 89, Barcelona 08041, Spain
Castellet, H:
Univ Autonoma Barcelona, Inst Josep Carreras, Hosp Santa Creu & St Pau, IIB St Pau,Lab Hematol,Hematol Dept, St Quinti 89, Barcelona 08041, Spain
Martinez, Clara:
Univ Autonoma Barcelona, Inst Josep Carreras, Hosp Santa Creu & St Pau, IIB St Pau,Lab Hematol,Hematol Dept, St Quinti 89, Barcelona 08041, Spain
González, N:
Univ Autonoma Barcelona, Inst Josep Carreras, Hosp Santa Creu & St Pau, IIB St Pau,Lab Hematol,Hematol Dept, St Quinti 89, Barcelona 08041, Spain
Guijarro, F:
Hosp Clin Barcelona, Unitat Hematopatol, IDIBAPS, Serv Anat Patol, Barcelona, Spain
Lloveras, N:
Hosp Dr Josep Trueta, Lab Hematol, ICO Girona, Girona, Spain
Pratcorona, M:
Univ Autonoma Barcelona, Inst Josep Carreras, Hosp Santa Creu & St Pau, IIB St Pau,Lab Hematol,Hematol Dept, St Quinti 89, Barcelona 08041, Spain
Gich, I:
Hosp Santa Creu & Sant Pau, Epidemiol Dept, Barcelona, Spain
Berenguer-Molins, P:
Hosp del Mar Res Inst HMRIB, Bioniformat Unit BU, MARData, Barcelona, Spain
Perera-Bel, J:
Hosp del Mar Res Inst HMRIB, Bioniformat Unit BU, MARData, Barcelona, Spain
Zamora, L:
Hosp Germans Trias i Pujol, Inst Josep Carreras, Hematol Dept, ICO Badalona, Badalona, Spain
Mascaró, M:
Hosp Son Llatzer, Hematol Dept, Palma De Mallorca, Spain
Sampol, A:
Hosp Son Espases, Hematol Dept, Palma De Mallorca, Spain
Garcia-Guiñón, A:
Hosp Arnau Vilanova, Serv Hematol, Lleida, Spain
Vives, S:
Hosp Germans Trias i Pujol, Inst Josep Carreras, Hematol Dept, ICO Badalona, Badalona, Spain
Tormo, M:
Univ Valencia, Hosp Clin Valencia, Lab Hematol, Valencia, Spain
Arnan, M:
Hosp Duran i Reynals, Inst Invest Biomed Bellvitge IDIBELL, Clin Hematol Dept, ICO, Barcelona, Spain
Villamor, N:
Hosp Clin Barcelona, Unitat Hematopatol, IDIBAPS, Serv Anat Patol, Barcelona, Spain
Nomdedéu, JF:
Univ Autonoma Barcelona, Inst Josep Carreras, Hosp Santa Creu & St Pau, IIB St Pau,Lab Hematol,Hematol Dept, St Quinti 89, Barcelona 08041, Spain
Green Submitted, gold
|